
==== Front
J Clin Transl Endocrinol
J Clin Transl Endocrinol
Journal of Clinical & Translational Endocrinology
2214-6237
Elsevier

S2214-6237(24)00037-1
10.1016/j.jcte.2024.100366
100366
Review
Advances in nucleic acid delivery strategies for diabetic wound therapy
Sarthi Soniya
Bhardwaj Harish
Kumar Jangde Rajendra rjandepy@gmail.com
⁎
University Institute of Pharmacy, Pt. Ravishankar Shukla University Raipur, Chhattisgarh 492010, India
⁎ Corresponding author. rjandepy@gmail.com
30 8 2024
9 2024
30 8 2024
37 10036615 3 2024
13 8 2024
22 8 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Graphical abstract

In recent years, the prevalence of diabetic wounds has significantly increased, posing a substantial medical challenge due to their propensity for infection and delayed healing. These wounds not only increase mortality rates but also lead to amputations and severe mobility issues. To address this, advancements in bioactive molecules such as genes, growth factors, proteins, peptides, stem cells, and exosomes into targeted gene therapies have emerged as a preferred strategy among researchers. Additionally, the integration of photothermal therapy (PTT), nucleic acid, and gene therapy, along with 3D printing technology and the layer-by-layer (LBL) self-assembly approach, shows promise in diabetic wound treatment. Effective delivery of small interfering RNA (siRNA) relies on gene vectors. This review provides an in-depth exploration of the pathophysiological characteristics observed in diabetic wounds, encompassing diminished angiogenesis, heightened levels of reactive oxygen species, and impaired immune function. It further examines advancements in nucleic acid delivery, targeted gene therapy, advanced drug delivery systems, layer-by-layer (LBL) techniques, negative pressure wound therapy (NPWT), 3D printing, hyperbaric oxygen therapy, and ongoing clinical trials. Through the integration of recent research insights, this review presents innovative strategies aimed at augmenting the multifaceted management of diabetic wounds, thus paving the way for enhanced therapeutic outcomes in the future.

Keywords

Diabetic wound healing
Nanotechnology
Targeted gene therapies
Nucleic acid
==== Body
pmcIntroduction

One of the main health issues for people with diabetes mellitus (DM) is impaired wound healing. Neuropathy and vascular injuries are two of the causes that contribute to this illness [1]. Additionally, a chronic hyperglycemic condition is caused by insufficient insulin synthesis or by the inability of insulin to interact with cells [2], the prevalence of diabetes in the population aged 18 to 99 is predicted to increase from 8.4 % in 2017 to 9.9 % in 2045. Wound healing in diabetic people is a challenging and dangerous health issue. Biochemical mechanisms such as homeostasis, inflammation, proliferation, and tissue remodeling are triggered during the healing process in non-diabetic individuals, according to Baltzis et al. However, the metabolic impairment of these processes is delayed in individuals with diabetes mellitus (DM), which might cause persistent wounds to form. Opportunistic infections can infect them if they are not appropriately treated, which frequently results in the amputation of the affected limbs [3].

Based on the kind of tissue, insulin operates by boosting the insulin receptors found in vertebrates, which facilitate the repair process' metabolic route. The repairing metabolic pathways' enhanced synthesis of signaling molecules including VEGF and protein kinase B, sometimes referred to as Akt, indicates that this hormone can promote cellular differentiation and proliferation. A thick epidermal layer developed in diabetic rats after topical insulin therapy shortened the time required for wound epithelialization. According to in vivo-secreted inflammatory mediators, this quicker wound healing may be linked to macrophage infiltration [4].

Diabetes has a complex pathophysiology that includes metabolic, vascular, immunological, and neuropathic elements that impair healing. Reduced tissue oxygenation is a result of slower circulation and microvascular dysfunction, both of which are associated with larger blood vessels in hyperglycemia. Reduced leukocyte migration into the wound, which increases sensitivities to infection, is also explained by diabetic individuals' blood vessel abnormalities [5]. The hyperglycemic surroundings themselves may impair leucocyte activity. Furthermore, if wounds are not properly recognized and treated, peripheral neuropathy can lead to numbness and a decreased perception of pain. The aspects that have been outlined are especially important for the lower limbs, especially the foot, which is more vulnerable to chronicization because of its increased exposure to even small lesions. Moreover, changes in motor and sympathetic nervous system function result in plantar pressure and physical deformity of the foot. Excessive skin dryness can also exacerbate fissures and minor lesions that go untreated [6].

Diabetic foot ulcers can occur in 15–25 % of patients during their lifetime, of which 40–80 % proceed to osteomyelitis due to severe infection that affects the bone [7]. North America may have a greater incidence, according to global epidemiological research. A substantial percentage of foot ulcer patients require hospitalization and surgical intervention, including amputation of the afflicted body part. Additionally, three years from the initial incident, the recurrence risk of a foot ulcer is higher than 50 % [8]. Consequently, poor wound healing in diabetes mellitus poses a substantial clinical challenge and financial burden [9], [10]. Notably, Diabetic foot ulcer therapy is more costly than normal diabetes care due to the higher incidence and prevalence of the disease [11], [12], [13].

The physiology of wound healing

The physiological phenomenon known as wound healing is intricate and arises when the skin's barrier function is compromised due to a loss of integrity. Due to the skin's high level of exposure to external irritants & the requirement to prevent internal infections, a quick defense mechanismmay be triggered often [14]. When tensile strength is typically only obtained to a maximum of 70 % of its earlier value, the skin can fully return to its natural state during physiologic repair [15]. This process proceeds in several levels, and four distinct phases are often identified: the stages of hemostasis, inflammation, proliferation, and remodeling shown in Fig. 1.Fig. 1 Phase of wound healing.

Hemostasis

Hemostasis, the process of clotting blood to stop bleeding, can be hampered in diabetic wounds by several conditions, including reduced immunological function, neuropathy, inadequate blood flow, and platelet dysfunction. It could need extra measures to achieve hemostasis in diabetic wounds, like regulating blood sugar levels, enhancing circulation, applying cutting-edge wound dressings, and keeping a close eye out for infections.

Inflammatory response

The inflammatory phase, which is preceded by the coagulation phase, is when the injured skin starts the clotting cascade by drawing platelets and creating a fibrin plug. In addition to dressing and shielding wounds, hemostasis depends on it. The clot's aggregated platelets act as a basis for the inflammatory cells' recruitment. By producing a range of cytokines and growth factors, including platelet-derived growth factor (PDGF) and transforming growth factor (TGF), they also attract different types of cells. Monocytes and neutrophils are among them; concomitant vasodilation facilitates their passage. The latter soon change into macrophages, which are believed to be the main cellular actors during this phase of inflammation since they again release cytokines and growth factors [16]. Furthermore, keratinocytes go to the site of injury, where local fibroblasts start to multiply. Within 48 to 72 h following the injury, these processes begin and quicken, helping to create the early granulation tissue [17].

Proliferation and remodeling

These phases are designed to encourage the closure of wounds. One of the first stages of wound closure is contraction, which is triggered by the formation of myofibroblasts, granulation tissue, keratinocyte migration, and extracellular matrix (ECM) protein synthesis. Fibroblasts, the major cell type in this phase, release collagen to start the process of repairing the wounded area. The early phases of wound healing are characterized by hypoxia, which promotes the release of growth factors and the migration and proliferation of all cell types. In actuality, hypoxia triggers the activation of HIF-1 and the stimulation of VEGF-A, one of HIF-1′s primary target genes [18]. Consequently, Active proliferation of endothelial cells is the cornerstone of neo-angiogenesis and is crucial for supplying the growing tissue with the support it needs. Wound healing is aided by VEGF-A's enhanced capillary density and restored blood flow. Following the initial proliferative phase is characterized by the growth of many, chaotic vessels. Following this, there is a maturation phase in which certain vessels mature and become durable by the recruitment of pericytes that generate antiangiogenic chemicals and vascular maturation factors [19]. Consequently, healing progresses toward a modelling step where collagen type I (which is typically seen in normal, non-injured tissue) replaces type III collagen, which first accumulates [20], the process of wound healing proceeds to restore the skin's physiologic structure while neovascularization is contained and returns to normal [21].

A chronic wound problem occurs as an ulcer or, in the opposite case, as an excessive healing event that, when the physiologic reparative process is interfered with, produces a hypertrophic scar or keloid. Hypertrophic scars are usually transitory, appearing in association with the patient's susceptibility and often regressing within six months. On the other hand, keloids form in people who are genetically predisposed, cover a larger area than the initial skin damage, and are permanent [22]. On the other hand, ulcers are common in diabetes individuals and frequently arise under ischemia situations. They are one of the main delayed effects of the illness.

Mechanism of wound healing

Multiple cell types, cytokines and growth factor interact in a complex network to facilitate wound healing. Three overlapping stages have traditionally been used to categorize the course of wound healing: remodeling, proliferation & inflammation. The inflammatorystage function is to control damage and get rid of infections. Although it might linger up to two weeks, inflammation usually passes after a few days [23]. Increased vascular permeability and the release of several chemoattractant facilitate the inflow of neutrophils and monocytes into a wound caused by the release of substance P, a neuropeptide, from the peripheral nerves [24]. Mature monocytes develop into macrophages during the inflammatory phase. The inflammatory phenotype (M1) of macrophages is involved in clearing debris and germs [25]. The inflammatory phase is terminated by macrophages that polarize towards the anti-inflammatory (M2) state of the wound when it is clear of foreign material. Angiogenesis, nerve regeneration fibrous tissue deposition combined with fibroplasia, and re-epithelialization are characteristics of the proliferative phase. About two to three days after the damage, proliferation begins. To start the creation of collagen, fibroblasts go into the wound region [26]. The process of wound closure is initiated and covered by the growth of keratinocytes. Pro-angiogenic substances, such as fibroblast growth factor 2 (FGF-2), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF), are produced to cause the onset of vascularization. Schwann cells help damaged nerves regenerate [27]. Usually, the proliferative period extends for many weeks. After an accident, the remodeling period might persist for months and starts two to three weeks later. Vascularization is decreased and granulation tissue is broken down by collagenases during the remodeling phase. As collagen type III breaks down, collagen type I is produced illustrated in Fig. 2 [28]. The injured tissue ages and becomes functioning again.Fig. 2 Mechanisms underlying activation of diabetic wounds.

To locally restore the wound to its natural healing process, TNAs are applied in a variety of methods. While the majority of the examples in this review focus on accelerating the healing of diabetic ulcers, we also provide some examples of how TNAs can be used to treat other types of chronic wounds, such as burns, pressure ulcers, venous ulcers, and myocardial infarction, each of which has specific requirements.

Nucleic acid delivery strategies

Gene therapy and nanotechnology are combined in nucleic acid-encapsulatedparticles to effectively suppress or express a particular gene for the treatment of chronic wounds [29]. Chronic wound healing can be sped up by expressing certain proteins, which is supported by gene transfer to the site of damage. For example, the use of viral vectors has transfectedpatients with diabeteswith VEGF to induce angiogenesis in chronic wounds, and the effect on wound healing has been reported. However, given that viral vectors might cause an immunological reaction and should always be handled carefully, it is preferable to employ non-viral carriers of nucleic acid, such as nanoparticles [30], [31]. SiRNA specifically targets matrix metalloproteinase (MMP), ganglioside-mono sialic acid 3 synthase (GM3S), and TNF-are among the genes that are overexpressed in chronic wounds. Allowing for the decrease of gene expression. For siRNA to be delivered in vivo and shield cells from physiological nucleases, a carrier must be incorporated into the cell. Human efforts delivering siRNA to cure many diseases have shown promise; nevertheless, main human trials failed because of substantial off-target effects or insufficient effectiveness. Before RNAi technology is used widely in clinical settings, it has to be further refined [32]. Table 1. depicted the different type of nucleic acid targeted systems.Table 1 Different types of nucleic acids targeted.

Targets	Nucleic acid	Delivery method/ carrier	Model system	Wound	Result	Ref.	
MMP-9	siRNA	Delivery of siRNA via Hyperbranched cationic polysaccharide derivatives
	In vivo, in vitro
healthy SD rats	After administering STZ, venous blood was extracted from the tail.
	MMP-9 of skin wound tissues, which subsequently improved wound recovery
	[56]	
prostaglandin transporter (PGT)	siRNA	DsiRNA-loaded gold nanoparticles
	In vitro, in vivo Wisterrats model	−	DsiRNA-AuNPs have antibacterial and therapeutic qualities, it is known that they can safely stimulate wound healing in vitro.
	[57]	
AZD8601	mRNA	Lipofectamine 2000(in situ citrate/saline (in vivo)	Human aortic smooth muscle in situ Live cells Mice C57BL/6BrdCrHsd-Tyrc (microvasculature of the ears) Leprdb/J mice (diabetes wound) B6.BKS(D)
healing)	Full-thickness cutaneous lesions on the dorsum of genetically diabetic mice, measuring one centimeter in diameter
	increased vascularization enhanced oxygenation of the tissues elevated reepithelialization
	[39]	
Res &VEGF	Plasmid	Hydrogel loading plasmid DNA	Male Sprague Dawley (SD) rats, age 6 weeks
	A copper cod was used to create two full-thickness burn wounds on either side of the dorsal skin (11 mm, 90 °C, 25 s).
	Rerelease has the potential to enhance wound healing by delivering a more gratifying anti-inflammatory response.
	[58]	
Plasmid encoding green fluorescence protein (GFP)	Plasmid DNA	Polyhedral oligomeric silsesquioxane (POSS) nanoparticles	In vivo, in vitro
16Male Sprague-Dawley rats, 200–300 g
	Full-thickness skin wounds were burnt for 50 s at 100 °C with a hot circular copper billet (diameter = 16 mm).
	Prolonged release for 35 days while maintaining a high transfection efficiency of genes. The wound healing rate is accelerated by the pAng encapsulated nanofibers, in addition to stimulating angiogenesis.	[59]	
M1 macrophages	miRNAs	exosomes	In vivo, in vitroMice B6.BKS(D)-Leprdb/J (db/db)
.
	8 mm skin wounds were made using a biopsy punch	MiR-222 suppression reduced anti-inflammatory gene expression even during a naïve LPS response, which in turn inhibited the production of many inflammatory mediators.	[60]	
TGF-b1	pDNA	Electroporation	In vivo, in vitro
C57BL/6 C57BKS.Cg-m+/+Leprdb female mice
	Wounds measuring 7 x 7 mm and fully thick on the back of a genetically diabetic mouse
	Increased angiogenesis
Increased reepithelization rate
Increased collagen synthesis	[61]	
VEGF	pDNA	Electroporation	In vivo, in vitro
Male SD rats	Rats' backs were incised using an 8 x 3 cm full-thickness incision
	Five days of elevated VEGF expression Necrosis of the distal region of RSFs was reduced by upregulating eNOS.	[62]	
PDGF-B	pDNA	Cholesterol and cationic liposomes
	Male SD rats in vivo and 3 T3 murine fibroblast cells in vitro
	2.1-cm incision made on the dorsal skin of an STZ-diabetic rat up to the level of the loose subcutaneous tissues	promotes re-epithelialization increased keratin and fibro collagen synthesis enhanced blood vessel creation
	[63]	
VEGF-A
PDGF-B	pDNA	Modified PLGA Nano sphere with PEI
	3T3 mouse fibroblast cells in vitro; female SD rats in vivo
	6-mm full-thickness skin wound on the diabetic rat S TZ's dorsal hind foot
	VEGF-A and PDGF-B expression levels were raised, which decreased the ulceration area.
	[64]	

siRNA

Using small interfering RNA (siRNA) to regulate gene expression has become a widely used TNA technique for persistent wounds. Using a matching siRNA, this method identifies a gene transcript that is over-expressed in chronic wounds with diabetes and targets it for knockdown. While siRNAs are now accessible for many genes, computational methods can assist in identifying suitable sequences for gene silencing in other cases. Here, we outline many siRNA genes that have been targeted in light of the biology underpinning chronic wound healing as well as techniques for delivering these genes locally to the wound bed [33].

The benefits of siRNA-based treatment might be significantly increased by two very recent technologies. Nanoneedles offer a unique way to transfer DNA and siRNA without requiring transfection reagents, however to the best of our knowledge, they are not directly employed for treating chronic wounds. Through the use of this technique, which is made possible by the ability of nanoneedles to permeate cell membranes and tissue, the medications interact directly with the target cells' cytoplasm through a process that is still unknown. This method can drastically alter TNA delivery by doing away with the difficulty of endosomal escape [34]. The efficiency of siRNA-based treatments may be significantly increased thanks to some of the recent work done in our lab on co-delivery of siRNA and Argonaute 2 (Ago2), the protein responsible for siRNA-mediated mRNA degradation. Gene knockdown produced by co-delivering self-assembled Ago2 and siRNA is more efficient and durable than siRNA alone..83 Such strategies might be modified for direct local administration to wound [35].

Plasmid

Although there have been many different strategies for delivering plasmids to promote wound healing, angiogenesis stimulators have been the primary focus of these strategies, with VEGF gene delivery being one of the most thoroughly researched. One team attempted to address the limited half-life of growth hormones by introducing EGF and VEGF plasmids. Diabetes was shown to reduce blood flow in the wound, whereas local VEGF plasmid administration restored blood flow by encouraging angiogenesis. Day 8 following the injury did not follow this pattern, although it did for days two and six. The study used sonoporation to help in plasmid absorption; however, because of its inability to affect broad sections of tissue efficiently and the possibility of damaging nearby tissue, sonoporation is not a therapeutically practical TNA delivery approach [36].

One group investigated the use of plasmid distribution to manage the protracted inflammatory condition associated with chronic wounds. They used a PEI-DNA combination linked to silica nanoparticles to deliver plasmids expressing the interleukin-10, an anti-inflammatory cytokine (IL-10). Since the intravenous administration ofThe half-life of IL 10 protein is only a few hours, TNA delivery is essential if extended activity is sought [37]. Although the plasmid's release kinetics were not disclosed, the levels of IL-10 peaked on day five or so. Reductions in TNFα and interleukin-1 β (IL-1β) transcript expression suggest that this method lessened the overall inflammatory status of the wounds. There is a need for research on this strategy's effectiveness in promoting chronic wound healing [38].

To improve epithelialization, researchers have finally employed plasmid DNA. Fig. 1 shows how the Saltzman group created nanofiber scaffolds by electrospinning poly (caprolactone) or poly (L-lactide) (PCL). The keratinocyte growth factor (FGF7, or KGF)-encoding plasmids were successfully transfected onto the surface thanks to the LbL assembly's addition of PEI and DNA. A burst release of around 10 % was seen in the scaffolds, and during the next week, an additional 5 % of the loaded plasmid was released. Increased keratinocyte proliferation, granulation tissue development, and epithelialization were how this tactic supported improved healing [39].

Anti-miRNA oligonucleotides (AMO)

The expression levels of non-protein-coding genes, including miRNAs, are not as well understood as those of protein-coding genes in wounds. Recent research is providing insight into the potential role of the miRNAs that have been experimentally linked to poor wound healing and discovered in screens [40], [41]. Number-inhibitingmiRNAs (anti-miRNA oligonucleotides, or AMOs) or mimicking miRNAs have been the subject of localized delivery experiments recently [42]. Due to their capacity to simultaneously regulate the expression of many genes, miRNA-based therapies provide both additional complexity and potential. Around 100 mRNAs' expression can be hypothesized to be controlled by a single miRNA [43]. The difficulty of targeting specific gene networks including protein-coding genes, where each gene requires a different sequencecan be mitigated in part by this special quality of miRNAs [44]. While it doesn't address polymeric delivery of AMOs and miRNA mimics, particularly for wound healing applications, a recent study from Day Lab goes into additional depth about these techniques [45].

Increasing VEGF through different channels is the foundation of many of the miRNA circuits that they target. Inhibitors of miR-615-5p, a miRNA that is approximately twice as abundant in diabetic skin as normal skin and is engaged in the VEGF-AKT-eNOS signaling cascade, were shown to promote wound healing by local injection. There was no usage of any medication delivery system in targeting miR-135a-3p has been shown to similarly alter the VEGF response, albeit it does so via the VEGF HIP1-p38K signaling axis [46]. There was no medication delivery vehicle employed, much like in the lab's prior work. With this methodology, they discovered a three-fold rise in CD31 positive, a marker of angiogenesis, in vivo [47]. Eventually, they demonstrated how SMAD1-mediated suppression of miR-26a may also cause angiogenesis in diabetic wound [48], [49].

Additionally, anti-miR-92a was studied as a potential therapeutic target for promoting angiogenesis following cutaneous wounds, bone fractures, myocardial infarction, limb ischemia, and vascular damage. Anti-miR-92a demonstrated re-epithelialization and granulation tissue creation that was somewhat equal to the recombinant growth factors, and it beat the effects of recombinant human VEGF and PDGF-BB on angiogenesis. The proof of principle study indicates that drug delivery systems might potentially augment the effects of intradermal injection, which was the method used to administer the AMO [50]. To improve geographical specificity and lower the likelihood of AMO's off-target effects entering the bloodstream, the Dimmeler and Heckel laboratories investigated if they might utilize light to initiate anti-miR-29a AMO activity. By preventing duplex formation with the miRNA in its caged state, the enclosed, light-activatable AMOs function, hence avoiding the blocking impact of the AMO. This photo-labile connection may be broken by the blue light emanating from a diode, enabling duplex synthesis. The scientists demonstrate that their AMO which is a light-activated system may be used to induce local suppression of miR-92a while having no effect on skin that has not been exposed to radiation. This approach offers an exciting way to manage local delivery of TNA, especially for accessible or shallow wounds where blue light can penetrate [51].

miRNA mimics

Anti-miRNA oligonucleotides (AMOs) are widely used to regulate transcription by controlling the amount of miRNA, however, some have produced endogenous miRNA mimics to promote upregulation as opposed to downregulation. While miRNA mimics are chemically manufactured and computationally developed, they behave similarly to miRNAs linked to certain biological pathways. Compared to endogenous miRNAs, they are more stable. Furthermore, because they have two strands, they may load straight into the RISC stands for RNA-induced silencing complex and start working right away without requiring the processing of the Dicer enzyme. However, due to their artificial character, experts have issued a warning that miRNA mimics might have strong off-target impacts on gene regulation [52].

Anti-sense oligonucleotides (ASOs)

Anti-sense oligonucleotides (ASOs), the final main type of therapeutic nucleic acid (TNAs) used for targeted delivery, regulate gene expression via three different mechanisms (Fig. 2).122 The Becker group looked at the long-term administration of an ASO against the gap junction protein Cx43. It was previously demonstrated that this gene is increased in diabetic wounds but downregulated near the wound margins to permit cell migration [53]. By increasing wound re-epithelialization, The balance of Cx43 levels was restored by an ASO against Cx43 [54]. They were able to sustain release over seven days by using collagen scaffolds coated with ASOs in PLGA or PCL. The controlled delivery of ASOs to target Cx43 for improved wound healing hasshown encouraging results. Specifically, the results indicated Although the wounds had less granulation tissue over time and were smaller after receiving local treatment with this ASO, indicating that the wounds healed over time [55].

The future of nucleic acid delivery of wound healing

Shortly, it is anticipated that the frequency of chronic wounds will rise making it an important worldwide concern. Hardly any novel treatments for chronic wounds have made it into clinical practice throughout the previous several decades of study. Delivering TNAs non-virally may provide the solution-new tactics are required. The most recent research on using TNAs for chronic wounds is outlined in this review. This article summarizes the pharmaceutical industry's interest in using TNA to treat wounds, in addition to the numerous drug delivery methods and therapeutic targets that have been studied.

The following features of a medication delivery system, in our opinion, are essential to changing the treatment methods for persistent wounds and eventually other healing problems:• Sustained TNA administration systems in wound dressings are probably more translational than injectable techniques because they may be adjusted to fit the wound's contour and cover the whole area, reducing the therapy's diffusion distance.

• Certain TNAs must be released by systems at different stages of the dynamic wound healing process, indicating that a phased release strategy would be the best option. The requirement for this might potentially be met by stimulus-responsive systems, which release TNAs only in response tofavourablecircumstances around the wound.

• A combination strategy would work best to promote healing in chronic wounds since several variables contribute to poor wound healing. With only one bandage, TNAs, for instance, can be used in concert to stimulate the M2 macrophage phenotype, encourage angiogenesis, and facilitate re-epithelialization and cell migration. It's important to consider when to release each of these parts.

• The historically poor effectiveness of TNA delivery may be improved by novel co-delivery techniques that increase the activity of the natural TNA mechanism, such as Ago2 andsiRNA co-delivery Novel non-viral delivery techniques, such as nanoneedles, have potential as well.

• Multiple gene modulation is a promising application of miRNA-based therapeutics; however, before clinical translation, more gene identification is essential. In many instances, the biological basis and possible therapeutic benefit are well-established.

Given the wealth of information on how genes are regulated in chronic and wound-healing diseases, nucleic acid methods offer the most efficient way to convert this understanding into treatments with significant promise. Improving the stability of nucleic acid vectors and producing RNA and DNA constructs have also led to recent advancements that make these therapeutic techniques considerably more affordable, feasible to manufacture, and readily available. In the following ten years, promising novel therapies for chronic wounds and other healing problems will result from the building of delivery systems that allow these medicines to reach the right cells and permit regulated and suitably phased-release [65].

Targeted gene therapy approaches

The discussion explores targeted gene therapy strategies, including stem cell therapy, gene/protein/peptide regulation, and the use of growth factors. These tactics are cutting-edge approaches meant to treat diabetic wound healing. The goal of therapy is to promote tissue regeneration and cellular proliferation at the wound site by utilizing growth factors. Modulating genes, proteins, and peptides offers new techniques to manipulate certain genetic or molecular targets to stimulate healing cascades or block harmful pathways. Using stem cells' capacity for regrowth to restore damaged tissues and coordinate healing processes, stem cell therapy presents a bright future. These specialized gene therapy approaches represent new directions in the treatment of diabetic wounds and offer customized, effective therapies.

Growth factor

Growth factorsarephysiologically active proteins that have a role in migration, metabolism, cell division and proliferation. Growth factors and cytokines control all healing processes physiologically. Growth factors attach to a particular receptor and activate several biochemical processes necessary for proper cell activity [66]. Growth factors promote modeling, inflammatory response, granulation of tissue, and angiogenesis, all of which are critical steps in the wound healing process. It has long been known that the pathophysiology of a diabetic wound will reduce the availability of growth factors [67]. Growth factors can be administered externally, but they are quickly biologically degraded by the proteases found in the wound bed. Moreover, the relatively large size and short half-life of growth factors, along with their toxicity at increased systemic dosages, indicate that traditional methods of delivering growth factors in a free form are inappropriate for efficiently transferring growth factors in the wound bed. Additionally, using a single growth factor to speed up wound closure in diabetic ulcers may not always be sufficient since several biomolecules are involved in the wound healing process [68]. These issues have led to the widespread use of growth factor encapsulation in nanoparticles, which improves the half-life, encapsulates multiple biomolecules, and protects against protease breakdown in the wound bed because of the nanoparticles' defensive qualities [69].

Many growth factors mediate, coordinate, and drive cellular interactions during normal wound healing, which is an important function they perform [70]. However, Several growth elements are in balance, and thrown off in diabetic wounds, harming angiogenesis, upsetting the extracellular matrix, and eventually impeding wound healing. Locally delivering endogenous therapeutic growth factors is one method of modulating diabetic wound signaling. To obtain therapeutic benefits, growth factors must be administered at large concentrations repeatedly. Furthermore, growth factors deteriorate quickly due to the action of proteases within the cells [71]. Consequently, a delivery system is needed to provide for the prolonged and regulated release of growth factors to the target in addition to maintaining growth factor activity. Presently, several systems such as it has been possible to apply hydrogels, nanofibers, and nanoparticles to apply growth factors to diabetic wounds [70], [72]. The primary pro-angiogenic factor in wounds that heal appropriately is VEGF-A according to earlier research [73]. Its expression peaked two to three days following the injury and increased steadily for around a week. Nevertheless, unlike normal mice, VEGF rises in db/db diabetic mice, but it is transient and rapidly falls to almost undetectable levels as granulation tissue develops. The short half-life of VEGF makes single-dose administration to wounds ineffective, according to clinical study data [74]. Repeated local administration of VEGF-165 accelerated diabetic wound angiogenesis and re-epithelialization [75], [76], [77]. Delivering VEGF using a gene activation technique should be used to get around the drawbacks of its brief half-life and recurrent administration. When compared to the quick delivery of growth factors or genes, Nucleic acid-carrier complexes can be physically encapsulated in hydrogels to prevent carrier breakdown and enable more sustained, focused transfection [78]. The primary constituent of hyaluronic acid (HA), the extracellular matrix (ECM), is a biomaterial that is extremely biocompatible and can stimulate angiogenesis [79]. Porous hydrogel made of HA with proangiogenic (pVEGF) plasmids inside for the goal of treating diabetic wounds through local gene therapy. These studies demonstrated that porous hydrogels acted as a barrier to wound healing that is mechanical and did not break down. Nevertheless, it did not seem that the transfected levels of pVEGF were sufficient to improve angiogenesis by enlarging or densifying blood vessels.

To stimulate their action in vivo (improving anti-proteolytic capacity) Devalliere et al. recombined keratinocyte growth factor (KGF) and cytoprotective peptides into a protein polymer to accelerate chronic wound healing (increasing wound bed angiogenesis). A single growth factor is less effective than two or more in promoting angiogenesis and the ensuing tissue healing, according to earlier research [80], [81]. For instance, when VEGF-A and FGF-2 are co-stimulated in vivo, cell migration and angiogenesis are much enhanced as opposed to when angiogenic growth factors are stimulated separately. Moreover, the vascular network was rapidly restored following the administration of dual agents, bFGF and VEGF. Table 2 illustrates the various growth factors incorporated into hydrogels, scaffolds, and nanoparticles in experimental studies focused on diabetic wound healing.Table 2 Growth factors in hydrogels, scaffolds, and nanoparticles used in experimental research on diabetic wound healing.

GFs	Characteristics	System	Result	Ref.	
NGF & bFGF	Good affinity and regulated release of GFs.
	Heparin hydrogel poloxamer
	Encouraging Schwann cell proliferation, remyelination, and axonal regeneration.
	[82]	
MIP-3α &IL-8	Steady bioactivity and cross-linking in place.
	Hydrogels made of gelatin
	Enhanced reepithelialization and increased collagen deposition.
	[83]	
VEGF, PDGF, bFGF and EGF	A sequenced release of several angiogenic factors.
	Nanofibrous membrane Col-HA-GN
	Increased vascular maturation and collagen deposition.
	[84]	
VEGF and bFGF	Release of many GFs under control.
	PLGA particles
	Achieved total re-epithelialization along with increased collagen deposition and granulation tissue development.
	[85]	
pVEGF plasmids	Regional gene transfer	HA-based hydrogels
	Improved the angiogenic response and encouraged wound closure.
	[86]	
KGF	GFs' activity in vivo can be improved by increasing their proteolytic resistance	Biopolymers of elastin
	Accelerating the healing process by increasing angiogenesis in the wound bed.
	[87]	
SDF-1	Thermoresponsive antioxidant
	Hydrogel PPCN
	Shown the greatest density of perfused blood vessels, rapid granulation tissue development, and epithelial maturation.
	[88]	
rh-aFGF	Strong biostability
	Hydrogel made of Carbomer
	Excellent skin wound healing promotion in diabetic rats after a full-thickness damage.
	[86]	
PDGF	biodegradable nanofibers with a sheath core
	Core-sheath nanofibrous
PLGA scaffolds	PDGF, vancomycin, and gentamycin were sustainably released over three weeks.
	[89]	
EGF	pH-variable hydrogel
	The hydrogels OHA and SCS
	Fibroblast proliferation, preservation of the internal structure of the tissue, and collagen and myofibril deposition are all encouraged.
	[90]	

Genes/Proteins/Peptides

Since individual miRNAs have pleiotropic effects, meaning they may control numerous genes and processes, it could be more beneficial to target miRNAs associated with illness. Approach than single-target angiogenic growth factors. It has been recently shown that miR-26a is a significant antagonist of angiogenesis in diabetic wounds; blocking this miRNA may be a useful diabetes treatment [49]. Wu and colleagues created PCN-miR/Col, a redox-modulatory hydrogel that is self-protective and strengthened by a ceria nanozyme. PCN-miR/Col guaranteed to maintain the pro-angiogenic miRNA's structural integrity in the oxidative milieu while also changing the oxidative wound microenvironment [91]. The “seed-and-soil” idea from the area of regenerative medicine was incorporated into the design toprovide proangiogenic miRNA signals to promote wound healing and tissue regeneration in diabetics(“seed”) and to reshape the oxidative wound microenvironment into one that is pro-regenerative. The suggested “seed-and-soil” approach can be used to regenerate and repair a variety of injured tissue that has been exposed to malfunctioning biomacromolecules and highly oxidative sick microenvironments. Li et al. developed a novel siRNA gene carrier, β-CD-(D3)7, designed to effectively inhibit MMP-9 expression, accelerate wound healing, and prevent organ damage and accumulation. The results suggest that this gene carrier could be utilized to formulate a new topical treatment for diabetic wounds, as shown in Table 3 [92].Table 3 Genes/Proteins/Peptides used in diabetic wound healing are summarized. Most of the Genes are miRNA, and there are both natural and synthetic peptides.

Gene /proteins / Peptides	Carrier	Function	Ref.	
Keapl siRNA	Lipoproteoplex functions as
	Normalize the ROS imbalance by activating the endogenous antioxidant systems mediated by Nrf2.
		
siRNA	Β-CD-(D3)7; coatings at the nanoscale.
	Reduction in MMP-9 expression
	[98]	
Plasmid DNA encoding VEGF	Ga-BDEs	Increased long-term VEGF expression
	[99]	
MiR-26a	Hydrogel PCN
	Pro-regenerative wound microenvironment and proangiogenic miRNA are provided.
	[91]	
DMOG	Fiber meshes PCL
	Lowering the expression of pro-inflammatory factors (TNF-α, IL-1β, IL-6, & TNF-α), raising the expression of anti-inflammatory factors (TGF-β1 & IL-4) and GFs (IGF-1, HB-EGF, NGF, & bFGF), and encouraging angiogenesis (CD-3 I & VEGF-α)
	[94]	
Heparin mimetic peptide amphiphiles	Nanofibers	Increased VEGF (major angiogenic growth factor) production and activity
	[100]	
Proline	IKFQFHFD hydrogel	Take off the MRSA biofilm
	[95]	
K2(SL)6K2	MDP hydrogel	They are perfect for tissue engineering techniques because they provide quick cellular penetration.
	[96]	
MMP-9 inhibitor (R) –ND-336	Linezolid	Reducing the harmful MMP-9 and reducing microphase infiltration to reduce inflammation
	[101]	
Laminin mimetic peptide SIKVAV	CS hydrogels	Increased the attachment and proliferation of BMSCs significantly
	[102]	
Integrin	Silk fibroin nanosheets
	Modulate angiogenesis and encourage the repair of diabetic ulcers
	[97]	
Nucleic acid	TFNAs	Antioxidant action through the signaling pathway Akt/Nrf2/HO-I
	[103]	
Heparin or Bemiparin	CS hydrogels	Improved wound healing of diabetes
	[93]	
Spider silk fusion proteins	Nanofibrous mats of AaSF	Effective matrix reconstruction in wounds
	[104]	

Cost and safety concerns still surround the use of genes and growth factors, even if their purpose is to improve angiogenesis and re-epithelialization. Peptides have frequently been added to hydrogels or scaffolds to give this Bioactivity of substrates for tissue engineering [93], [94], [95]. To encourage angiogenesis and speed up the healing of diabetic wounds, Using peptide hydrogel with several domains, Carrejo et al. incite a moderate inflammatory response and rapidly infiltrate cells [96]. Angiogenesis regulation and the promotion of diabetic ulcer healing are possible with a pro-survival peptide-engineered silk fibroin Nano sheet with therapeutic properties that bind integrin [97].

Stem cells/exosomes

Stem cell therapy is one of the most promising therapies for diabetic wounds since stem cells can create a range of bioactive compounds, including growth factors to restore tissue/organ function [105], [106], [107]. With the help of human ADSCs, or adipose-derived stem cells, and epidermal growth factor (EGF)-loaded microcapsules, the collagen hydrogel successfully restores blood perfusion and promotes tissue regeneration [108]. Hydrogels containing acrylate hyaluronic acid (AHA) are also used to treat type 1diabetes wounds using pluripotent stem cells (hiPSCs). Furthermore, the skin wound healing process is successfully promoted by Gingival mesenchymal stem cells (GMSCs) added to the sponge made of chitosan and silk hydrogel [109]. Macrophages M1, particularly M2, possess the capacity to safeguard and regulate immune function as the body is mending. Through the production of growth factors and anti-inflammatory cytokines like VEGF and TGF-β, they also aid in reducing inflammation and promoting angiogenesis and proliferation. This can expedite the diabetic chronic wound healing phase from inflammation to proliferation and remodeling. Immune cells may cling to, grow, travel through, and regenerate on 97 different types of hydrogels.

Exosomes are membrane vesicles that are nanoscale and range in diameter from 30 to 150 nm. They are identified by the expression of exosome-associated markers such as Tgs101, Alix, CD9, CD63, and CD81. They are also known to transport functional complexes of proteins, lipids, and nucleic acids [110], [111], [112]. Because of this, exosomes are thought to be both natural RNA carriers for treating diseases and means of delivering drugs [113], [114], [115]. Furthermore, one of the most important secretory products of bone marrow mesenchymal stem cells is believed to be exosomes, which can promote intercellular communication and help in the healing of wounds [116], [117], [118], and it can greatly enhance human umbilical vein endothelial cells (HUVECs) motility, proliferation, and angiogenesis. FHE hydrogel based on polypeptides contains adipose-derived mesenchymal stem cell exosomes (AMSCs-exo) (F127/OHA-EPL). Multifunctional biological activity properties are provided by FHE@exo hydrogel, in addition to injectability, self-healing, antibacterial activity, and exosome release. An injectable, thermosensitive, multipurpose polysaccharide-based dressing (FEP) that promotes angiogenesis and the healing of diabetic wounds was developed by Wang et al. It also features a pH-responsive exosome release mechanism that is maintained [119], [120]. Exosome-based hydrogels hold significant potential for the treatment of skin regeneration and chronic wounds, particularly those associated with diabetes. Consequently, they could be utilized as a therapeutic tool in the future. Table 4 provides a summary of the use of stem cells and exosomes for the effective management of diabetic wounds.Table 4 Summary of Stem Cell/Exosomes towards effective control of diabetic wounds.

Cell type	System	Characterization	Ref.	
SMCs exosomes	Dressings for CS wounds
	Overexpression exosomes of microRNA-126-3p.
	[121]	
ECM-free biomimetic nanofibrous
	Biomimetic nanofibrous scaffolds for the extracellular matrix of bones
	Without the use of a growth factor.
	[122]	
Decellularized Extracellular Matrix
	dECM hydrogels	Genetically modified hydrogels.
	[123]	
M2 macrophage phenotype
	Hydrogels HHA
	Numerous pathways modulating angiogenesis and immunocompromise.
	[124]	
ADSCs	Cryogels GSL
	To enhance angiogenesis, ADSCs are delivered on antioxidant GS scaffolds coated with GSL, an endothelial basement protein.
	[125]	
MSCs	RGO particles
	Acellular Dermal Composite Scaffold
	[105]	
ASCs	PEG-hydrogelized gelatin
	Allogenic ASC delivery in vivo
	[106]	
hiPSCs	Hydrogels AHA
	Constructing vascularized structures
	[126]	
hASC exosomes	hASC-exos using electroporation to transport miR-21-5p as cargo
	ASC-exos and miR-21 combined to provide synergistic therapeutic effects
	[127]	
ASCs exosomes	FEP clothing
	Adhesive, thermosensitive, injectable multipurpose dressing
	[128]	
GMCs exosomes	Hydrogel sponge CS/Silk
	Combination of hydrogels and exosomes produced from GMSC
	[129]	
AMSCs exosomes	Hydrogels OHA
	The bioactive multifunctional features include stimuli-responsive exosome release, self-healing, antibacterial activity, and injectability.
	[130]	

Drugs employed in the treatment of wounds in individuals with diabetes

In light of the clinical and pharmacological challenges associated with diabetes-related wound infections, the optimal drug delivery method should distribute the medication into the skin's deeper layers. When paired with the hydrogel/nanoparticle characteristics, The long-term release of drugs to the wound may be stabilized and healing promoted by the nanoscale local drug delivery system [131]. Currently, several intricate delivery methods have been created to prolong the duration that drugs are delivered [132], [133], [134]. A hybrid hydrogel of polydopamine and nanocellulose that is multi-responsive and capable of wound healing and medication release (tetracycline hydrochloride) [135]. The drug may be delivered continuously for more than twenty-four hours, and there is no explosive drug release at the beginning of the release process. With long-term drug delivery capabilities, the greatest drug release ratio was 77 %. HIF-1α accumulation has been induced by deferoxamine (DFO), a medication that mimics hypoxia. additionally, it has been demonstrated that HIF-1α is crucial for the healing of wounds [136]. Hydrogel/scaffolds laden with DFO rapidly induce angiogenesis for the regeneration of diabetic skin by upregulating HIF-1α [137], [138], [139]. Furthermore, when both bioglass (BG) and DFO are combined with When combined, sodium alginate hydrogel, BG, and DFO can increase the production of HIF-1α and VEGF, which will vascularize the wound sites and improve wound healing in diabetic skin [140]. Hydrogels filled with drugs and cells have been used to treat wounds recently shown promise. Injectable hydrogels that are sensitive to both pH and glucose can be used to contain protein medications such as insulin and living cells called fibroblasts [141]. This hydrogel patch promotes neovascularization and collagen deposition, which may hasten the healing of diabetic wounds [142].

Drug load and release control can be achieved by optimizing certain aspects of hydrogels and composite scaffolds. Drugs are released in an “on-off” manner with long-term drug delivery performance when scaffolds/hydrogels are exposed to specific stimulation (pH or near-infrared laser irradiation). This avoids explosive drug release at the start of the release phase. Precise administration, which may be attained progressively as a wound is healing in different stages, should be the focus of our future study. Since hydrogels may transport more medications, growth factors, peptides, and DNA which support angiogenesis and wound healingthey provide a promising new tool for wound healing research. Determining the optimal hydrogel breakdown rate and water content is also essential to facilitate faster wound healing while maintaining complex release and mechanical support for the wound bed. However, to attain high functional efficiency in terms of permeability, stability, and therapeutic efficacy, more precise topical drug delivery systems must be designed. These systems could be integrated with 3D technology due to the increasing issue of drug resistance and the specific physicochemical properties required. Table 5 details the delivery systems for drugs and natural macromolecular bioactive substances that effectively manage chronic and diabetic wounds.Table 5 Delivery of drug/natural macromolecular bioactive substances systems with effective control of chronic/diabetic wounds.

Drugs	Drug delivery system	Function	Ref.	
Deferoxamine (DMO)	TDDS, scaffolds, nanofibrous materials, and multifunctional hydrogels.
	Enhances the expression of HIF-I α and elevates that of VEGF.
	[138], [139], [143]	
Ciprofloxacin	Polymer sponges with cyclodextrin and CS
	There is no danger of toxicity to the body when local medications are released.
	[133]	
Insulin	Hydrogels that are injectable
	Hydrogels that respond to both glucose and PH.
	[144]	
Statins	scaffolding for tissue engineering
	eNOS/NO up-regulation in situ.
	[145]	
Curcumin	Nanoparticles of chitosan and gelatin
	MMP9-responsive drug delivery system; antioxidant and anti-inflammatory.
	[146]	
Dimethyloxalylglycine (DMGO)	Electrospun fibrous membrane with pores
	controlled release DMGO medication
	[147]	
Snail glycosaminoglycan	Polysaccharide sulfate
	increased the speed at which a full-thickness incision in diabetic mice healed.
	[132]	
Kirenol	Diterpenoid	Promote the growth of fibroblasts and angiogenesis
	[132]	
Quercetin	A scaffold made of collagen, nanomaterials, and drugs
	Enhancing the formation of new blood vessels and collagen in diabetic wound healing.
	[148]	
Herbal extract of didymocarpuspedicellatus	Hydrogels Pdmaema-HA
	Increased cellular repair as well as improved cutaneous wound healing.
	[149]	

Drug delivery system based on nanotechnology

Novel drug-delivery systems (DDSs) may enhance the efficacy of current and future therapies for these challenging clinical problems [150]. One of the most concentrated areas of study in recent times has been nanotechnology therapy of diabetic patients and related issues. The benefits of nanomaterials (which are between 1 and 100 nm in size) are their controllable size, adaptability in application, & physiochemical characteristics that may be tuned. Greater surface area to volume ratio Nanomaterials can promote cell adherence and may be able to contain more surface functionalized active components to speed up particular regeneration processes [151]. The benefits of using nanotechnology-based wound healing techniques include topical medication administration, cellular selectivity, as well as the controlled, steady release of drug-encapsulated substances for the required amount of time until the wound healing [152], [153]. Nanoparticles are ideal for topical distribution in the context of wound healing because of their interactions with the biological target and improved penetration at the wound sites. Moreover, by adjusting the nanoparticle dispersion, medications that are encapsulated might be supplied continuously and at a pace that is appropriate for them [154]. Table 6 depicts the nanoparticle-based delivery for diabetic wound repair.Table 6 Nanoparticles and 3D printing technology for diabetic wound repair.

Technology
	System	Result	Ref.	
Nanoparticles	pSi NPs	Up to 7 days after treatment, FnAb-loaded pSi NPs treated with proteases exhibit intact and functional antibodies.
	[159]	
	rGO and ADM-GO-PEG/Que.
	Improved wound healing by increased angiogenesis, collagen production, and deposition.
	[165], [166]
	
CW/NPs/HBC-HG hydrogel; MEL-NPs; CS/PVA/ZnO nanofibrous membranes; chitosan/PVA nanofibers.
	The substrate has antimicrobial properties and no known cytotoxicity.
	[167]	
3D printing	PU&dCA composite dressing in four layers.
	Not only permits the movement of wound exudates from the wound bed to the dressing but also permits the carefully regulated return of a fluid containing bioactive ions to the wound bed to promote angiogenesis.
	[168]	
Gel-pio inner layer and PCL hydrophobic outer layer.
	Show a high degree of water resistance and a high level of bacterial adherence.
	[169]	
Patches with microneedles
	Control diabetic mice's blood glucose levels for up to 40 h in the normoglycemic range.
	[170]	
Nanofibers oriented either vertically or radially combined with BMSCs.
	Collagen deposition, angiogenesis, and granulation tissue development are all improved.
	[171]	
SA/PEG scaffold filled with Saturejacuneifolia
	3D-printed scaffolds have demonstrated a strong antimicrobial impact.

	[172]	
Gelatin cryogels filled with silver comprise the upper layer, while 3D-printed scaffolds loaded with PDGF-BB comprise the lower layer.
	In vivo, the substrate was able to encourage angiogenesis, collagen deposition, granulation tissue development, and re-epithelialization.	[170]	

The utilization of topical delivery of Nanotherapeutics presents significant benefits for chronic wounds, like diabetic wounds. This is because (a) The medicinal substance is only applied temporarily or until the wound heals, and (b) Cell-type specificity and a variety of factorial variables work together to effectively promote skin regeneration and wound healing. Smart nanomaterials based on nanotechnology include liposomes, hydrogel, polymeric, inorganic, and lipid nanoparticles; sometimes known as nanofibrous formations. These nanoparticle-loaded foams can contain extracellular substrates, peptides, growth factors, and antibiotics. To speed up the healing process, it is also possible to infuse two distinct therapeutic agents together that have different properties [155]. Oppositely, there are two possible ways that the drug might bind to the surface matrix of nanoparticles: either it is absorbed, distributed, or dissolves around the particle and becomes trapped in an aqueous core with surrounding shell-like structures [156]. The biological system will release the medications contained in the nanoparticles by a combination of dissolution, reduction, distension, and diffusion. Additionally, when included with additional drugs in a nanocomposite system, nanoparticles can be encased in nanofiber, hydrogel, foam, films, and nanocrystals. This enables a synergistic interaction between the target medicine and the nanoparticles, leading to a unique concept for a wound dressing that promotes better wound healing [157]. These dressings promote the adhesion and migration of keratinocytes and fibroblasts, assisting in the re-epithelialization of wounds and the synthesis of collagen. Their composition resembles theendogenous extracellular matrix's (ECM) topological appearance [158].

Advanced technology

Many advances are currently widely used in the treatment of diabetic wounds. Multifunctional scaffolds, layer-by-layer (LBL) approach, photothermal treatment (PTT), 3D printing technology, and hyperbaric oxygen therapy are a few of them.

Photothermal therapy

Treatment for chronic wounds with photothermal therapy (PTT) is one therapeutic method used. Specifically engineered nanoparticles interact with a near-infrared (NIR) laser to produce localized heat. Challenge wound healing can be aided by PTT's ability to specifically cause cell death in the region of nanoparticles by utilizing this thermal energy. The bio-mineralization approach of joining BSA-CuS nanoparticles demonstrated bactericidal properties near-infrared for wound healing, demonstrating the presence of bovine serum albumin (BSA) and copper sulfide (CuS) in cow-like serum protein. Furthermore, pathogen Staphylococcus aureus as well as heat-resistant Escherichia coli and ampicillin-resistant Escherichia coli may be successfully inhibited by MoS2- BNN6. Although PTT based on nanoparticles holds a lot of promise for treating diabetic wound infections, PTT therapy requires careful investigation and particular clinical studies because the heat in the area can potentially gravely damage adjacent healthy tissue [159].

LBL self-assembly, or layer-by-layer technique

LBL self-assembly, or layer-by-layer is one of several straightforward techniques that some biomaterials might use to enhance their biological properties. Biomedical uses the LBL self-assembly technology extensively for distribution from a variety of material surfaces. Furthermore, the LBL-modified composite material possesses high hydrophilicity, mechanical characteristics, and stability [160], [161]. The LL self-assembly technique is widely preferred due to its ability to transfer electrostatic force on the polyelectrolyte matrix surface with an opposing charge, thereby enhancing drug release continuously. Additionally, it is cost-effective, simple to operate, and controllable without any potential complications [162]. Furthermore, to produce fast diabetic wound healing, therapeutically appropriate amounts of siRNA may be incorporated and released in a regulated manner via self-assembled nanometer-scale coatings. Thus, using LBL to change localized protein expression levels has a big influence on treating site-specific diseases like cancer, DFUs, heart disease, and transplant rejection.

3D-printed

3D-printed structures for wound healing aim to address many benefits: the ability to change attributes of layered wound dressings, such as thickness, proximity, or hole value; dependable medicine stacking; the use of a variety of materials; and O2 availability through a hollow design. 3D printing advances were employed to build sodium alginate-polyethylene glycol structures by mixing different fixes with 1, 3, 4, and 5 wt% of PEG on sodium alginate [163], [164]. 3D printing platforms have demonstrated outstanding antibacterial qualities, particularly against high gram counts of pathogens [163]. This is outlined in Table 6, which details the application of 3D printing technology for diabetic wound repair.

Negative pressure wound healing

Negative pressure was applied to injuries in 1997, and NPWT was first implemented in the USA. These devices have the potential to enhance blood flow, preserve a moist wound environment, remove exudate from the site, apply pressure to encourage wound healing and provide additional benefits that may be deficient in wounds caused by diabetes [166]. Specifically for complex surgical wounds, NPWT has shown to be an interesting and emerging use. This innovative technique may promote healing and reduce the size of wounds. NPWT entails connecting a wound filler to a vacuum source to apply negative pressure to the area of the wound. The use of a computer-controlled retraction device, which continuously injects saline and an antiseptic or antibiotic solution into the wound, is one novel advancement in NPWT. This modification enhances the therapeutic potential of NPWT by making it simpler to transport advantageous chemicals to the wound site specifically [167].

Hyperbaric oxygen therapy

Hyperbaric oxygen is used in wound healing because, among other things, it stimulates angiogenesis, increases security, and encourages the formation and multiplication of fibroblasts. That being said, there has been significant discussion over the applicability of these guidelines because they have not even remotely proven to be accurate. Importantly, restricted oxygen supply is ineffective, hence this procedure is carried out on patients in a hyperbaric oxygen chamber [168], [169]. Current study suggests that in wounds where an ischemic diabetic ulcer has exhibited hypoxia, hyperbaric oxygen therapy should be considered. A scientific initiative is currently being conducted to explore these issues by comparing hyperbaric oxygen therapy with modern wound care techniques to prevent amputations in non-healing ulcers in individuals with diabetes. This observation was no longer suitable for evaluating outcomes such as amputation [170], [171].

Clinical trials

Certainly, clinical trials focusing on diabetic wound healing are crucial for advancing medical treatment in this area. These trials typically aim to evaluate the effectiveness and safety of various interventions or treatments designed to improve wound healing in individuals with diabetes. Here's a generalized outline of how such a clinical trial might be structured shown in Table 7.Table 7 Clinical trial on diabetic wounds.

Country	Identifier	Study title	Phase	Sponsor/ collaborator	Status
	
Mexico	NCT03782155	HMB and Glutamine Supplementation's Effect on Bloody Area Wound Healing
	Phase 4	Hospital General de Mexico	Withdraw	
Florida	NCT00967837	Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics (wounds)
	Phase 2
Phase 3	Florida Atlantic University	Interventional	
Indianapolis, Indiana	NCT00777712	Mechanisms Underlying Impaired Diabetic Wound Healing	Phase 2	Dr. Sashwati Roy, Indiana University (Responsible Party)	Observational	
Lund, Sweden	NCT05608187	The Impact of HMB and Glutamine Supplementation on the Healing of Bloody Area Wounds	Phase 2	Ilya Pharma (Responsible Party)	Interventional	
North Carolina	NCT06028386	Diabetic Foot Ulcers and the AC5® Advanced Wound System	Not Applicable	Arch Therapeutics (Responsible Party)	Interventional	
Singapore,	NCT03863054	A Clinical Trial with Observational Design Investigating the Impact of Topical Oxygen Therapy (NATROXTM) on the Healing Rates of Chronic Diabetic Foot Ulcers	Not applicable	Singapore General Hospital	Observational	
Giza, Egypt	NCT05517863	The Impact of Infrared and 650 nm Combined Laser on the Surface Area of Chronic Diabetic Foot Ulcers: (wounds)
	Not applicable	Heidy F. Ahmed, Cairo University	Interventional	
Guntersville, Alabama, united states	NCT04450693	Human umbilical cord cryopreserved (TTAX01) for advanced, complicated, non-healing diabetic foot ulcers (AMBULATE DFU II)
	Phase 3	Tissue Tech Inc.	Interventional
	
Arizona
Phoenix, Arizona
Sylmar, California	NCT03230175	Phase 2 Pilot Study of Participants Receiving Standard Care and Cryopreserved Umbilical Cord Allograft for Complex Non-Healing Diabetic Foot Ulcers (TTAX01)
	Phase 2	Tissue Tech Inc.	Interventional	
Mashhad, razavi Khorasan, Iran, Islamic	NCT05850611	The Impact of Oral MB and PRP-FG Combination Therapy on Patients with Diabetic Foot Ulcers That Don't Heal
	Daryoush Hamidi Alamdari, PhD, Mashhad University of Medical Sciences	Early Phase 1	Interventional	
Indianapolis, Indiana, United States	NCT05191758	Nutritional Regulation of Leukocyte Function (FPP Supplement)
	Dr. Sashwati Roy, Indiana University	Not Applicable	Interventional	
Vista, California, United States	NCT04207099	Comparing X vs. Standard of Care (WAR) for Wound Area Reduction of Non-healing DFUs Using MolecuLight
	MolecuLight Inc.	Not Applicable	Observational	

Conclusion

In conclusion, the escalating prevalence of diabetic wounds presents a formidable medical challenge, characterized by heightened risks of infection and delayed healing, ultimately contributing to elevated mortality rates, amputations, and impaired mobility. To address these challenges, researchers have increasingly turned to advanced bioactive molecules such as genes, growth factors, proteins, peptides, stem cells, and exosomes, harnessing targeted gene therapies as a preferred strategy. Additionally, the amalgamation of photothermal therapy (PTT), nucleic acid, and gene therapy, alongside innovations in 3D printing technology and layer-by-layer (LBL) self-assembly techniques, holds significant promise for diabetic wound treatment. Effective delivery of small interfering RNA (siRNA) necessitates adept gene vector systems. This comprehensive review elucidates the intricate pathophysiological underpinnings of diabetic wounds, including diminished angiogenesis, elevated reactive oxygen species levels, and compromised immune responses. Furthermore, it explores recent advancements in nucleic acid delivery, targeted gene therapy, advanced drug delivery systems, negative pressure wound therapy (NPWT), hyperbaric oxygen therapy, and ongoing clinical trials. By synthesizing recent research insights, the review proposes innovative strategies aimed at enhancing the multifaceted management of diabetic wounds, thereby fostering improved therapeutic outcomes in the future.

CRediT authorship contribution statement

Soniya Sarthi: Writing – original draft. Harish Bhardwaj: Writing – review & editing, Conceptualization. Rajendra Kumar Jangde: Writing – review & editing, Visualization, Supervision, Formal analysis, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Authors are thankful to the the Head of the Department, University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur for the support during the study. This study did not receive any external funding.
==== Refs
References

1 Saharan A. Verma I. Dhanawat M. Parkash C. Nano-Drug Delivery Systems in the Treatment of Wound Healing Nanotechnol. Drug Deliv 2024 Jenny Stanford Publishing 439 467
2 Jangde R. Srivastava S. Singh M.R. Singh D. In vitro and In vivo characterization of quercetin loaded multiphase hydrogel for wound healing application Int J Biol Macromol 115 2018 1211 1217 29730004
3 Burgess J.L. Wyant W.A. Abdo Abujamra B. Kirsner R.S. Jozic I. Diabetic wound-healing science Medicina (B Aires) 57 2021 1072
4 Gao D. Zhang Y. Bowers D.T. Liu W. Ma M. Functional hydrogels for diabetic wound management APL Bioeng 5 2021
5 Chauhan S. Gulia M. Singh R.P. Jhawat V. Diabetic wound: pathophysiology, complications and treatment strategies Curr Protein Pept Sci 25 2024 200 205 37909438
6 Chauhan S. Chalotra R. Rathi A. Saini M. Deol S. Lard M. Current approaches in healing of wounds in diabetes and diabetic foot ulcers Curr Bioact Compd 19 2023 104 121
7 Geraghty T. Laporta G. Current health and economic burden of chronic diabetic osteomyelitis Expert Rev Pharmacoecon Outcomes Res 19 2019 279 286 30625012
8 Lazzarini P.A. Raspovic K.M. Meloni M. van Netten J.J. A new declaration for feet’s sake: Halving the global diabetic foot disease burden from 2% to 1% with next generation care Diabetes Metab Res Rev 40 2024 e3747 37997627
9 Vora D.J. Sheth D.S. Zariwala R. Patel V.D. Thakker D.G. Katara S. Study of micro organisms in diabetic foot and its management Www Ijphrd Com 14 2023 80
10 Tan S.T. Aisyah P.B. Firmansyah Y. Nathasia N. Budi E. Hendrawan S. Effectiveness of secretome from human umbilical cord mesenchymal stem cells in gel (10% SM-hUCMSC Gel) for chronic wounds (Diabetic and Trophic Ulcer)–Phase 2 clinical trial J Multidiscip Healthc 1763–1777 2023
11 Liu S. Zhao Y. Li M. Nie L. Wei Q. Okoro O.V. Bioactive wound dressing based on decellularized tendon and GelMA with incorporation of PDA-loaded asiaticoside nanoparticles for scarless wound healing Chem Eng J 466 2023 143016
12 Syed M.H. Al-Omran M. Ray J.G. Mamdani M. de Mestral C. High-intensity hospital utilization among adults with diabetic foot ulcers: a population-based study Can J Diabetes 46 2022 330 336 35527204
13 Sen C.K. Human wound and its burden: updated 2022 compendium of estimates Adv Wound Care 12 2023 657 670
14 Picoli C. de C. Birbrair A. Li Z. Pericytes as the orchestrators of vasculature and adipogenesis Genes (Basel) 15 2024 126 38275607
15 Sawaya A.P. Vecin N.M. Burgess J.L. Ojeh N. DiBartolomeo G. Stone R.C. Calreticulin: a multifunctional protein with potential therapeutic applications for chronic wounds Front Med 10 2023 1207538
16 Matoori S. Veves A. Mooney D.J. Advanced bandages for diabetic wound healing Sci Transl Med 13 2021 eabe4839 33731435
17 Gushiken L.F.S. Beserra F.P. Bastos J.K. Jackson C.J. Pellizzon C.H. Cutaneous wound healing: an update from physiopathology to current therapies Life 11 2021 665 34357037
18 Bormann D. Gugerell A. Ankersmit H.J. Mildner M. Therapeutic application of cell secretomes in cutaneous wound healing J Invest Dermatol 143 2023 893 912 37211377
19 Kuddushi M. Shah A.A. Ayranci C. Zhang X. Recent advances in novel materials and techniques for developing transparent wound dressings J Mater Chem B 11 2023 6201 6224 37306212
20 Pastar I. Ojeh N. Glinos G.D. Stojadinovic O. Tomic-Canic M. Physiology and pathophysiology of wound healing in diabetes Diabet Foot Med Surg Manag 2018 109 130
21 Chen J. Ye P. Gu R. Zhu H. He W. Mu X. Neuropeptide substance P: a promising regulator of wound healing in diabetic foot ulcers Biochem Pharmacol 115736 2023
22 Chattopadhyay A.N. Jiang M. Makabenta J.M.V. Park J. Geng Y. Rotello V. Nanosensor-enabled detection and identification of intracellular bacterial infections in macrophages Biosensors 14 2024 360 39194589
23 Grigore A. Coman O.A. Păunescu H. Costescu M. Fulga I. Latest insights into the in vivo studies in murine regarding the role of TRP channels in wound healing—a review Int J Mol Sci 25 2024 6753 38928459
24 Suvas S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis J Immunol 199 2017 1543 1552 28827386
25 Hauger P.C. Hordijk P.L. Shear stress-induced AMP-activated protein kinase modulation in endothelial cells: its role in metabolic adaptions and cardiovascular disease Int J Mol Sci 25 2024 6047 38892235
26 Karimzadeh F. Fard E.S. Nadi A. Malekzadeh R. Elahian F. Mirzaei S.A. Advances in skin gene therapy: utilizing innovative dressing scaffolds for wound healing, a comprehensive review J Mater Chem B 2024
27 Gharatape A. Sadeghi-Abandansari H. Seifalian A. Faridi-Majidi R. Basiri M. Nanocarrier-based gene delivery for immune cell engineering J Mater Chem B 12 2024 3356 3375 38505950
28 Segers V.F.M. Bringmans T. De Keulenaer G.W. Endothelial dysfunction at the cellular level in three dimensions: severity, acuteness, and distribution Am J Physiol Circ Physiol 325 2023 H398 H413
29 Krasilnikova O. Yakimova A. Ivanov S. Atiakshin D. Kostin A.A. Sosin D. Gene-activated materials in regenerative dentistry: narrative review of technology and study results Int J Mol Sci 24 2023 16250 38003439
30 Li S. Zhang M.-Y. Yuan J. Zhang Y.-X. Nano-vaccines for gene delivery against HIV-1 infection Expert Rev Vaccines 22 2023 315 326 36945780
31 Mavi A.K. Kumar M. Singh A. Prajapati M.K. Khabiya R. Maru S. Progress in non-viral delivery of nucleic acid: advancement in biomedical technology Integr Biomater Gene Ther 2023 281 322
32 Rabbani P.S. Zhou A. Borab Z.M. Frezzo J.A. Srivastava N. More H.T. Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing Biomaterials 132 2017 1 15 28391065
33 Shi Y. Yang X. Min J. Kong W. Hu X. Zhang J. Advancements in culture technology of adipose-derived stromal/stem cells: implications for diabetes and its complications Front Endocrinol (Lausanne) 15 2024 1343255 38681772
34 Patilas C. Varsamos I. Galanis A. Vavourakis M. Zachariou D. Marougklianis V. the role of interleukin-10 in the pathogenesis and treatment of a spinal cord injury Diagnostics 14 2024 151 38248028
35 Li J. Wu C. Wang W. He Y. Elkayam E. Joshua-Tor L. Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference Proc Natl Acad Sci 115 2018 E2696 E2705 29432194
36 Arunadevi N. Kirubavathy S.J. Three-dimensional approaches based on nanotechnology towards wound management 2024 Nanotechnological Asp. Next-Generation Wound Manag., Elsevier in 245 280
37 J.W. Ronström, Exploring Mesolimbic Circuitry Modulation by Opiates, Interleukin-10, and Psychostimulants, (2024).
38 Wang X. Coradin T. Hélary C. Modulating inflammation in a cutaneous chronic wound model by IL-10 released from collagen–silica nanocomposites via gene delivery Biomater Sci 6 2018 398 406 29337327
39 Shaabani E. Sharifiaghdam M. Faridi-Majidi R. De Smedt S.C. Braeckmans K. Fraire J.C. Gene therapy to enhance angiogenesis in chronic wounds Mol Ther Acids 29 2022 871 899
40 Binder A.K. Bremm F. Dörrie J. Schaft N. Non-coding RNA in tumor cells and tumor-associated myeloid cells—function and therapeutic potential Int J Mol Sci 25 2024 7275 39000381
41 Li J. Feng R. Zhang X. Hou W. Zhang Y. Li J. miR-181d targets BCL2 to regulate HCT-8 cell apoptosis and parasite burden in response to Cryptosporidium parvum infection via the intrinsic apoptosis pathway Vet Parasitol 110237 2024
42 Ozdemir D. Feinberg M.W. MicroRNAs in diabetic wound healing: pathophysiology and therapeutic opportunities Trends Cardiovasc Med 29 2019 131 137 30143275
43 Das S. Micro target: MicroRNA target prediction and validation with experimentally positive and negative examples Plant Cell Biotechnol Mol Biol 25 2024 26 34
44 Klees C. Alexandri C. Demeestere I. Lybaert P. The role of microRNA in spermatogenesis: is there a place for fertility preservation innovation? Int J Mol Sci 25 2023 460 38203631
45 Kapadia C.H. Luo B. Dang M.N. Irvin-Choy N. Valcourt D.M. Day E.S. Polymer nanocarriers for MicroRNA delivery J Appl Polym Sci 137 2020 48651 33384460
46 Tzani A. Haemmig S. Cheng H.S. Pérez-Cremades D. Heuschkel M.A. Jamaiyar A. FAM222A, part of the BET-regulated basal endothelial transcriptome, is a novel determinant of endothelial biology and angiogenesis—brief report Arterioscler Thromb Vasc Biol 44 2024 143 155 37942611
47 Icli B. Wu W. Ozdemir D. Li H. Haemmig S. Liu X. MicroRNA-135a-3p regulates angiogenesis and tissue repair by targeting p38 signaling in endothelial cells FASEB J 33 2019 5599 30668922
48 Icli B. Wara A.K.M. Moslehi J. Sun X. Plovie E. Cahill M. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling Circ Res 113 2013 1231 1241 24047927
49 Icli B. Nabzdyk C.S. Lujan-Hernandez J. Cahill M. Auster M.E. Wara A.K.M. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a J Mol Cell Cardiol 91 2016 151 159 26776318
50 Gallant-Behm C.L. Piper J. Dickinson B.A. Dalby C.M. Pestano L.A. Jackson A.L. A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds Wound Repair Regen 26 2018 311 323 30118158
51 Chin J.S. Madden L.E. Phillips A.R.J. Chew S.Y. Becker D.L. Bio-mimicking acellular wet electrospun scaffolds promote accelerated integration and re-epithelialization of full-thickness dermal wounds Bioengineering 9 2022 324 35877375
52 Yasarbas S.S. Inal E. Yildirim M.A. Dubrac S. Lamartine J. Mese G. Connexins in epidermal health and diseases: insights into their mutations, implications, and therapeutic solutions Front Physiol 15 2024 1346971 38827992
53 Barbu A. Neamtu B. Zăhan M. Iancu G.M. Bacila C. Mireșan V. Current trends in advanced alginate-based wound dressings for chronic wounds J Pers Med 11 2021 890 34575668
54 Sayed L.H. Badr G. Omar H.-E.-D.-M. Elghaffar S.K.A. Sayed A. Bee gomogenat enhances the healing process of diabetic wounds by orchestrating the connexin-pannexin gap junction proteins in streptozotocin-induced diabetic mice Sci Rep 13 2023 19961 37968314
55 Gilmartin D.J. Soon A. Thrasivoulou C. Phillips A.R.J. Jayasinghe S.N. Becker D.L. Sustained release of Cx43 antisense oligodeoxynucleotides from coated collagen scaffolds promotes wound healing Adv Healthc Mater 5 2016 1786 1799 27253638
56 Lan B. Wu J. Li N. Pan C. Yan L. Yang C. Hyperbranched cationic polysaccharide derivatives for efficient siRNA delivery and diabetic wound healing enhancement Int J Biol Macromol 154 2020 855 865 32198034
57 Li N. Yang L. Pan C. Saw P.E. Ren M. Lan B. Naturally-occurring bacterial cellulose-hyperbranched cationic polysaccharide derivative/MMP-9 siRNA composite dressing for wound healing enhancement in diabetic rats Acta Biomater 102 2020 298 314 31751808
58 Władyczyn A. Simiczyjew A. Nowak D. Wądzyńska J. John Ł. Novel hybrid composites based on double-decker silsesquioxanes functionalized by methacrylate derivatives and polyvinyl alcohol as potential materials utilized in biomedical applications Biomater Adv 146 2023 213290
59 Wang P. Huang S. Hu Z. Yang W. Lan Y. Zhu J. In situ formed anti-inflammatory hydrogel loading plasmid DNA encoding VEGF for burn wound healing Acta Biomater 100 2019 191 201 31586729
60 Li W. Wu D. Zhu S. Liu Z. Luo B. Lu L. Sustained release of plasmid DNA from PLLA/POSS nanofibers for angiogenic therapy Chem Eng J 365 2019 270 281
61 Lee P.-Y. Chesnoy S. Huang L. Electroporatic delivery of TGF-β1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice J Invest Dermatol 123 2004 791 798 15373787
62 Liarte S. Bernabé-García Á. Nicolás F.J. Role of TGF-β in skin chronic wounds: a keratinocyte perspective Cells 9 2020 306 32012802
63 Paskal W. Gotowiec M. Stachura A. Kopka M. Włodarski P. VEGF and other gene therapies improve flap survival—a systematic review and meta-analysis of preclinical studies Int J Mol Sci 25 2024 2622 38473869
64 Kadunc Polajnar L. Lainšček D. Gašperšič R. Sušjan-Leite P. Kovačič U. Butinar M. Engineered combinatorial cell device for wound healing and bone regeneration Front Bioeng Biotechnol 11 2023 1168330 37234478
65 Pei J. Yan Y. Palanisamy C.P. Jayaraman S. Natarajan P.M. Umapathy V.R. Materials-based drug delivery approaches: recent advances and future perspectives Green Process Synth 13 2024 20230094
66 Diao W. Li P. Jiang X. Zhou J. Yang S. Progress in copper-based materials for wound healing Wound Repair Regen 32 2024 314 322 37822053
67 Bhardwaj H. Jangde R.K. Development and characterization of ferulic acid-loaded chitosan nanoparticle embedded-hydrogel for diabetic wound delivery Eur J Pharm Biopharm 114371 2024
68 Le Z. Ramos M.C. Shou Y. Li R.R. Cheng H.S. Jang C.J.M. Bioactive sucralfate-based microneedles promote wound healing through reprogramming macrophages and protecting endogenous growth factors Biomaterials 311 2024 122700
69 Park J.W. Hwang S.R. Yoon I.-S. Advanced growth factor delivery systems in wound management and skin regeneration Molecules 22 2017 1259 28749427
70 Ezhilarasu H. Ramalingam R. Dhand C. Lakshminarayanan R. Sadiq A. Gandhimathi C. Biocompatible aloe vera and tetracycline hydrochloride loaded hybrid nanofibrous scaffolds for skin tissue engineering Int J Mol Sci 20 2019 5174 31635374
71 Toufanian S. Mohammed J. Winterhelt E. Lofts A. Dave R. Coombes B.K. A Nanocomposite dynamic covalent cross-linked hydrogel loaded with fusidic acid for treating antibiotic-resistant infected wounds ACS Appl Bio Mater 7 2024 1947 1957
72 Bhardwaj H. Khute S. Sahu R. Jangde R.K. Advanced drug delivery system for management of chronic diabetes wound healing Curr Drug Targets 24 2023 1239 1259 37957907
73 Salahshour P. Abdolmaleki S. Monemizadeh S. Gholizadeh S. Khaksar S. Nanobiomaterials/bioinks based scaffolds in 3D bioprinting for tissue engineering and artificial human organs Adv. Biol. Earth Sci. 9 2024
74 Huang X. Zheng X. Xu Z. Yi C. ZnO-based nanocarriers for drug delivery application: From passive to smart strategies Int J Pharm 534 2017 190 194 29038062
75 Jin S.-E. Jin H.-E. Synthesis, characterization, and three-dimensional structure generation of zinc oxide-based nanomedicine for biomedical applications Pharmaceutics 11 2019 575 31689932
76 S. Sampath, S. Alagappan, G.S. Priyanga, R.K. Gupta, A. Behera, T.A. Nguyen, Shape memory ceramics, in: Adv. Flex. Ceram., Elsevier, 2023: pp. 13–24.
77 Kumar V. Kewlani P. Singh A. Sanjay A.K. Gautam V. Mahalingam Rajamanickam, Multifunctional liposomes to attain targeting, stimuli sensitive drug release and imaging cancer Adv Drug Deliv Methods Appl, Springer 2023 49 87
78 Lin Y. Lin J. Hong Y. Development of chitosan/poly-γ-glutamic acid/pluronic/curcumin nanoparticles in chitosan dressings for wound regeneration J Biomed Mater Res Part B Appl Biomater 105 2017 81 90
79 Blažević F. Milekić T. Romić M.D. Juretić M. Pepić I. Filipović-Grčić J. Nanoparticle-mediated interplay of chitosan and melatonin for improved wound epithelialisation Carbohydr Polym 146 2016 445 454 27112895
80 Egle K. Salma I. Dubnika A. From blood to regenerative tissue: how autologous platelet-rich fibrin can be combined with other materials to ensure controlled drug and growth factor release Int J Mol Sci 22 2021 11553 34768984
81 Sharma S. Parmar A. Kori S. Sandhir R. PLGA-based nanoparticles: a new paradigm in biomedical applications TrAC Trends Anal Chem 80 2016 30 40
82 Li R. Li Y. Wu Y. Zhao Y. Chen H. Yuan Y. Heparin-poloxamer thermosensitive hydrogel loaded with bFGF and NGF enhances peripheral nerve regeneration in diabetic rats Biomaterials 168 2018 24 37 29609091
83 Yoon D.S. Lee Y. Ryu H.A. Jang Y. Lee K.-M. Choi Y. Cell recruiting chemokine-loaded sprayable gelatin hydrogel dressings for diabetic wound healing Acta Biomater 38 2016 59 68 27109762
84 Sathyaraj W.V. Prabakaran L. Bhoopathy J. Dharmalingam S. Karthikeyan R. Atchudan R. Therapeutic efficacy of polymeric biomaterials in treating diabetic wounds—an upcoming wound healing technology Polymers (Basel) 15 2023 1205 36904445
85 Lai H.-J. Kuan C.-H. Wu H.-C. Tsai J.-C. Chen T.-M. Hsieh D.-J. Tailored design of electrospun composite nanofibers with staged release of multiple angiogenic growth factors for chronic wound healing Acta Biomater 10 2014 4156 4166 24814882
86 Hui Q. Zhang L. Yang X. Yu B. Huang Z. Pang S. Higher biostability of rh-aFGF-carbomer 940 hydrogel and its effect on wound healing in a diabetic rat model ACS Biomater Sci Eng 4 2018 1661 1668 33445322
87 Devalliere J. Dooley K. Hu Y. Kelangi S.S. Uygun B.E. Yarmush M.L. Co-delivery of a growth factor and a tissue-protective molecule using elastin biopolymers accelerates wound healing in diabetic mice Biomaterials 141 2017 149 160 28688286
88 Zhu Y. Hoshi R. Chen S. Yi J. Duan C. Galiano R.D. Sustained release of stromal cell derived factor-1 from an antioxidant thermoresponsive hydrogel enhances dermal wound healing in diabetes J Control Release 238 2016 114 122 27473766
89 Lee C.-H. Liu K.-S. Cheng C.-W. Chan E.-C. Hung K.-C. Hsieh M.-J. Codelivery of sustainable antimicrobial agents and platelet-derived growth factor via biodegradable nanofibers for repair of diabetic infectious wounds ACS Infect Dis 6 2020 2688 2697 32902952
90 Zhu J. Jiang G. Hong W. Zhang Y. Xu B. Song G. Rapid gelation of oxidized hyaluronic acid and succinyl chitosan for integration with insulin-loaded micelles and epidermal growth factor on diabetic wound healing Mater Sci Eng C 117 2020 111273
91 Wu H. Li F. Shao W. Gao J. Ling D. Promoting angiogenesis in oxidative diabetic wound microenvironment using a nanozyme-reinforced self-protecting hydrogel ACS Cent Sci 5 2019 477 485 30937375
92 Li N. Luo H.-C. Ren M. Zhang L.-M. Wang W. Pan C.-L. Efficiency and safety of β-CD-(D3) 7 as siRNA carrier for decreasing matrix metalloproteinase-9 expression and improving wound healing in diabetic rats ACS Appl Mater Interfaces 9 2017 17417 17426 28447455
93 Cifuentes A. Gómez-Gil V. Ortega M.A. Asúnsolo Á. Coca S. San Román J. Chitosan hydrogels functionalized with either unfractionated heparin or bemiparin improve diabetic wound healing Biomed Pharmacother 129 2020 110498
94 Zhang Q. Oh J.-H. Park C.H. Baek J.-H. Ryoo H.-M. Woo K.M. Effects of dimethyloxalylglycine-embedded poly (ε-caprolactone) fiber meshes on wound healing in diabetic rats ACS Appl Mater Interfaces 9 2017 7950 7963 28211272
95 Wang J. Chen X.-Y. Zhao Y. Yang Y. Wang W. Wu C. pH-switchable antimicrobial nanofiber networks of hydrogel eradicate biofilm and rescue stalled healing in chronic wounds ACS Nano 13 2019 11686 11697 31490650
96 Carrejo N.C. Moore A.N. Lopez Silva T.L. Leach D.G. Li I.-C. Walker D.R. Multidomain peptide hydrogel accelerates healing of full-thickness wounds in diabetic mice ACS Biomater Sci Eng 4 2018 1386 1396 29687080
97 Yang H. Lai C. Xuan C. Chai M. Liu X. Chen Y. Integrin-binding pro-survival peptide engineered silk fibroin nanosheets for diabetic wound healing and skin regeneration Chem Eng J 398 2020 125617
98 Castleberry S.A. Almquist B.D. Li W. Reis T. Chow J. Mayner S. Self-assembled wound dressings silence MMP-9 and improve diabetic wound healing in vivo Adv Mater 28 2016 1809 1817 26695434
99 Lou D. Luo Y. Pang Q. Tan W.-Q. Ma L. Gene-activated dermal equivalents to accelerate healing of diabetic chronic wounds by regulating inflammation and promoting angiogenesis Bioact Mater 5 2020 667 679 32420517
100 Senturk B. Mercan S. Delibasi T. Guler M.O. Tekinay A.B. Angiogenic peptide nanofibers improve wound healing in STZ-induced diabetic rats ACS Biomater Sci Eng 2 2016 1180 1189 33465876
101 Peng Z. Nguyen T.T. Song W. Anderson B. Wolter W.R. Schroeder V.A. Selective MMP-9 inhibitor (R)-ND-336 alone or in combination with linezolid accelerates wound healing in infected diabetic mice ACS Pharmacol Transl Sci 4 2020 107 117 33615165
102 Chen S. Zhang M. Shao X. Wang X. Zhang L. Xu P. A laminin mimetic peptide SIKVAV-conjugated chitosan hydrogel promoting wound healing by enhancing angiogenesis, re-epithelialization and collagen deposition J Mater Chem B 3 2015 6798 6804 32262473
103 Maita K.C. Avila F.R. Torres-Guzman R.A. Sarabia-Estrada R. Zubair A.C. Quinones-Hinojosa A. In Vitro Enhanced Osteogenic Potential of Human Mesenchymal Stem Cells Seeded in a Poly (Lactic-co-Glycolic) Acid Scaffold: A Systematic Review Craniomaxillofac Trauma Reconstr 17 2024 61 73 38371215
104 Chouhan D. Das P. Thatikonda N. Nandi S.K. Hedhammar M. Mandal B.B. Silkworm silk matrices coated with functionalized spider silk accelerate healing of diabetic wounds ACS Biomater Sci Eng 5 2019 3537 3548 33405736
105 Fu J. Zhang Y. Chu J. Wang X. Yan W. Zhang Q. Reduced graphene oxide incorporated acellular dermal composite scaffold enables efficient local delivery of mesenchymal stem cells for accelerating diabetic wound healing ACS Biomater Sci Eng 5 2019 4054 4066 33448807
106 Dong Y. Rodrigues M. Kwon S.H. Li X. Brett E.A. Elvassore N. Acceleration of diabetic wound regeneration using an in situ–formed stem-cell-based skin substitute Adv Healthc Mater 7 2018 1800432
107 Mizuno H. Tobita M. Uysal A.C. Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine Stem Cells 30 2012 804 810 22415904
108 Morris A.H. Stamer D.K. Kunkemoeller B. Chang J. Xing H. Kyriakides T.R. Decellularized materials derived from TSP2-KO mice promote enhanced neovascularization and integration in diabetic wounds Biomaterials 169 2018 61 71 29631168
109 Shi Q. Qian Z. Liu D. Sun J. Wang X. Liu H. GMSC-derived exosomes combined with a chitosan/silk hydrogel sponge accelerates wound healing in a diabetic rat skin defect model Front Physiol 8 2017 904 29163228
110 Zhao W. Li K. Li L. Wang R. Lei Y. Yang H. Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles in Disease Therapy Int J Mol Sci 25 2024 7715 39062956
111 Nayak S.S. Jangde R.K. Formulation and design optimization of repaglinide loaded transferosomes for management of type II diabetes mellitus Natl J Pharma Sci 3 2023 115 125
112 Sobajima S. Saita Y. Iwaguro H. Tsubosaka M. Kuroda R. Sun Z. Adipose-derived stem cells: Use in clinical medicine 2023 Princ. Gender-Specific Med., Elsevier in 213 229
113 Wubbolts R. Leckie R.S. Veenhuizen P.T.M. Schwarzmann G. Möbius W. Hoernschemeyer J. Proteomic and biochemical analyses of human B cell-derived exosomes: potential implications for their function and multivesicular body formation J Biol Chem 278 2003 10963 10972 12519789
114 Batrakova E.V. Kim M.S. Using exosomes, naturally-equipped nanocarriers, for drug delivery J Control Release 219 2015 396 405 26241750
115 Haney M.J. Klyachko N.L. Zhao Y. Gupta R. Plotnikova E.G. He Z. Exosomes as drug delivery vehicles for Parkinson’s disease therapy J Control Release 207 2015 18 30 25836593
116 Zhao J. Zhou C. Xiao Y. Zhang K. Zhang Q. Xia L. Oxygen generating biomaterials at the forefront of regenerative medicine: advances in bone regeneration Front Bioeng Biotechnol 12 2024 1292171 38282892
117 Dadashzadeh A. Moghassemi S. Amorim C.A. Bioprinting of a liposomal oxygen-releasing scaffold for ovary tissue engineering 2024 Tissue Eng Part A
118 Pulido-Escribano V. Torrecillas-Baena B. Dorado G. Gálvez-Moreno M.Á. Camacho-Cardenosa M. Casado-Díaz A. Combination of biomaterials and extracellular vesicles from mesenchymal stem-cells: new therapeutic strategies for skin-wound healing Appl Sci 13 2023 2702
119 Pan C. Xu P. Zheng Y. Wang Y. Chen C. Fu S. Preparation of therapy-grade extracellular vesicles from adipose tissue to promote diabetic wound healing Front Bioeng Biotechnol 11 2023 1129187 37034267
120 Wang Z. Chen T. Li X. Guo B. Liu P. Zhu Z. Oxygen-releasing biomaterials for regenerative medicine J Mater Chem B 11 2023 7300 7320 37427691
121 Tao S.-C. Guo S.-C. Li M. Ke Q.-F. Guo Y.-P. Zhang C.-Q. Chitosan wound dressings incorporating exosomes derived from microRNA-126-overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model Stem Cells Transl Med 6 2017 736 747 28297576
122 Gao W. Jin W. Li Y. Wan L. Wang C. Lin C. A highly bioactive bone extracellular matrix-biomimetic nanofibrous system with rapid angiogenesis promotes diabetic wound healing J Mater Chem B 5 2017 7285 7296 32264178
123 Morris A.H. Lee H. Xing H. Stamer D.K. Tan M. Kyriakides T.R. Tunable hydrogels derived from genetically engineered extracellular matrix accelerate diabetic wound healing ACS Appl Mater Interfaces 10 2018 41892 41901 30424595
124 Liu S. Yu J. Zhang Q. Lu H. Qiu X. Zhou D. Dual cross-linked HHA hydrogel supplies and regulates MΦ2 for synergistic improvement of immunocompromise and impaired angiogenesis to enhance diabetic chronic wound healing Biomacromolecules 21 2020 3795 3806 32786521
125 Tyeb S. Shiekh P.A. Verma V. Kumar A. Adipose-derived stem cells (ADSCs) loaded gelatin-sericin-laminin cryogels for tissue regeneration in diabetic wounds Biomacromolecules 21 2019 294 304 31771325
126 Shen Y.-I. Cho H. Papa A.E. Burke J.A. Chan X.Y. Duh E.J. Engineered human vascularized constructs accelerate diabetic wound healing Biomaterials 102 2016 107 119 27328431
127 Lv Q. Deng J. Chen Y. Wang Y. Liu B. Liu J. Engineered human adipose stem-cell-derived exosomes loaded with miR-21-5p to promote diabetic cutaneous wound healing Mol Pharm 17 2020 1723 1733 32233440
128 Wang M. Wang C. Chen M. Xi Y. Cheng W. Mao C. Efficient angiogenesis-based diabetic wound healing/skin reconstruction through bioactive antibacterial adhesive ultraviolet shielding nanodressing with exosome release ACS Nano 13 2019 10279 10293 31483606
129 Yu M. Liu W. Li J. Lu J. Lu H. Jia W. Exosomes derived from atorvastatin-pretreated MSC accelerate diabetic wound repair by enhancing angiogenesis via AKT/eNOS pathway Stem Cell Res Ther 11 2020 1 17 31900237
130 Wang C. Wang M. Xu T. Zhang X. Lin C. Gao W. Engineering bioactive self-healing antibacterial exosomes hydrogel for promoting chronic diabetic wound healing and complete skin regeneration Theranostics 9 2019 65 30662554
131 Melnikova N. Malygina D. Balakireva A. Peretyagin P. Revin V. Devyataeva A. The Effect of Betulin Diphosphate in Wound Dressings of Bacterial Cellulose-ZnO NPs on Platelet Aggregation and the Activity of Oxidoreductases Regulated by NAD (P)+/NAD (P) H-Balance in Burns on Rats Molecules 26 2021 5478 34576949
132 Wu Y. Zhou Z. Luo L. Tao M. Chang X. Yang L. A non-anticoagulant heparin-like snail glycosaminoglycan promotes healing of diabetic wound Carbohydr Polym 247 2020 116682
133 Amiel A.G. Palomino-Durand C. Maton M. Lopez M. Cazaux F. Chai F. Designed sponges based on chitosan and cyclodextrin polymer for a local release of ciprofloxacin in diabetic foot infections Int J Pharm 587 2020 119677
134 Jyoti K. Malik G. Chaudhary M. Sharma M. Goswami M. Katare O.P. Chitosan and phospholipid assisted topical fusidic acid drug delivery in burn wound: Strategies to conquer pharmaceutical and clinical challenges, opportunities and future panorama Int J Biol Macromol 161 2020 325 335 32485249
135 Liu L. Wang X. Zhou Y. Cai M. Lin K. Fang B. The synergistic promotion of osseointegration by nanostructure design and silicon substitution of hydroxyapatite coatings in a diabetic model J Mater Chem B 8 2020 2754 2767 32196041
136 Xing D. Liu L. Marti G.P. Zhang X. Reinblatt M. Milner S.M. Hypoxia and hypoxia-inducible factor in the burn wound Wound Repair Regen 19 2011 205 213 21362088
137 Chen H. Jia P. Kang H. Zhang H. Liu Y. Yang P. Upregulating Hif-1α by hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis relative cells in diabetic wound Adv Healthc Mater 5 2016 907 918 26891197
138 Chen H. Guo L. Wicks J. Ling C. Zhao X. Yan Y. Quickly promoting angiogenesis by using a DFO-loaded photo-crosslinked gelatin hydrogel for diabetic skin regeneration J Mater Chem B 4 2016 3770 3781 32263315
139 Duscher D. Neofytou E. Wong V.W. Maan Z.N. Rennert R.C. Inayathullah M. Transdermal deferoxamine prevents pressure-induced diabetic ulcers Proc Natl Acad Sci 112 2015 94 99 25535360
140 Shen H. Ma Y. Qiao Y. Zhang C. Chen J. Zhang R. Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis Molecules 29 2024 2050 38731540
141 Wu Y. Li X. Xie W. Jankovic J. Le W. Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells Neurochem Int 57 2010 198 205 20546814
142 Ghufran H. Mehmood A. Azam M. Butt H. Ramzan A. Yousaf M.A. Curcumin preconditioned human adipose derived stem cells co-transplanted with platelet rich plasma improve wound healing in diabetic rats Life Sci 257 2020 118091
143 Rani S. Ritter T. The exosome-A naturally secreted nanoparticle and its application to wound healing Adv Mater 28 2016 5542 5552 26678528
144 Zhao L. Niu L. Liang H. Tan H. Liu C. Zhu F. pH and glucose dual-responsive injectable hydrogels with insulin and fibroblasts as bioactive dressings for diabetic wound healing ACS Appl Mater Interfaces 9 2017 37563 37574 28994281
145 Yang Y. Yin D. Wang F. Hou Z. Fang Z. In situ eNOS/NO up-regulation—a simple and effective therapeutic strategy for diabetic skin ulcer Sci Rep 6 2016 30326 27453476
146 Liu J. Chen Z. Wang J. Li R. Li T. Chang M. Encapsulation of curcumin nanoparticles with MMP9-responsive and thermos-sensitive hydrogel improves diabetic wound healing ACS Appl Mater Interfaces 10 2018 16315 16326 29687718
147 Ren X. Han Y. Wang J. Jiang Y. Yi Z. Xu H. An aligned porous electrospun fibrous membrane with controlled drug delivery–an efficient strategy to accelerate diabetic wound healing with improved angiogenesis Acta Biomater 70 2018 140 153 29454159
148 Chu J. Shi P. Yan W. Fu J. Yang Z. He C. PEGylated graphene oxide-mediated quercetin-modified collagen hybrid scaffold for enhancement of MSCs differentiation potential and diabetic wound healing Nanoscale 10 2018 9547 9560 29745944
149 Mittal A.K. Bhardwaj R. Arora R. Singh A. Mukherjee M. Rajput S.K. Acceleration of wound healing in diabetic rats through poly dimethylaminoethyl acrylate–hyaluronic acid polymeric hydrogel impregnated with a Didymocarpus pedicellatus plant extract ACS Omega 5 2020 24239 24246 33015440
150 Whittam A.J. Maan Z.N. Duscher D. Wong V.W. Barrera J.A. Januszyk M. Challenges and opportunities in drug delivery for wound healing Adv Wound Care 5 2016 79 88
151 Olteanu G. Neacșu S.M. Joița F.A. Musuc A.M. Lupu E.C. Ioniță-Mîndrican C.-B. Advancements in Regenerative Hydrogels in Skin Wound Treatment: A Comprehensive Review Int J Mol Sci 25 2024 3849 38612660
152 Jackson J.E. Kopecki Z. Cowin A.J. Nanotechnological advances in cutaneous medicine J Nanomater 2013 2013 16
153 Goyal R. Macri L.K. Kaplan H.M. Kohn J. Nanoparticles and nanofibers for topical drug delivery J Control Release 240 2016 77 92 26518723
154 Soldevila-Boixader L. Fernández A.P. Laguna J.M. Uçkay I. Local antibiotics in the treatment of diabetic foot infections: a narrative review Antibiotics 12 2023 124 36671326
155 Adhalrao S.B. Jadhav K.R. Patil P.L. Kadam V.J. Engineering Platelet Membrane Imitating Nanoparticles for Targeted Therapeutic Delivery Curr Pharm Biotechnol 25 2024 1230 1244 37539932
156 Gelperina S. Kisich K. Iseman M.D. Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis Am J Respir Crit Care Med 172 2005 1487 1490 16151040
157 Berthet M. Gauthier Y. Lacroix C. Verrier B. Monge C. Nanoparticle-based dressing: the future of wound treatment? Trends Biotechnol 35 2017 770 784 28645529
158 Hamdan S. Pastar I. Drakulich S. Dikici E. Tomic-Canic M. Deo S. Nanotechnology-driven therapeutic interventions in wound healing: potential uses and applications ACS Cent Sci 3 2017 163 175 28386594
159 Turner C.T. McInnes S.J.P. Melville E. Cowin A.J. Voelcker N.H. Delivery of flightless I neutralizing antibody from porous silicon nanoparticles improves wound healing in diabetic mice Adv Healthc Mater 6 2017 1600707
160 Christke S. Gibson A.G. Grigoriou K. Mouritz A.P. Multi-layer polymer metal laminates for the fire protection of lightweight structures Mater Des 97 2016 349 356
161 Shi Y. Wan D. Huang J. Liu Y. Li J. Stable LBL self-assembly coating porous membrane with 3D heterostructure for enhanced water treatment under visible light irradiation Chemosphere 252 2020 126581
162 Oroojalian F. Jahanafrooz Z. Chogan F. Rezayan A.H. Malekzade E. Rezaei S.J.T. Synthesis and evaluation of injectable thermosensitive penta-block copolymer hydrogel (PNIPAAm-PCL-PEG-PCL-PNIPAAm) and star-shaped poly (CL─ CO─ LA)-b-PEG for wound healing applications J Cell Biochem 120 2019 17194 17207 31104319
163 Ghosh S. Nandi S. Basu T. Nano-antibacterials using medicinal plant components: an overview Front Microbiol 12 2022 768739
164 Kankariya N. Laing R.M. Wilson C.A. Textile-based compression therapy in managing chronic oedema: Complex interactions Phlebology 36 2021 100 113 32819205
165 Thangavel P. Kannan R. Ramachandran B. Moorthy G. Suguna L. Muthuvijayan V. Development of reduced graphene oxide (rGO)-isabgol nanocomposite dressings for enhanced vascularization and accelerated wound healing in normal and diabetic rats J Colloid Interface Sci 517 2018 251 264 29428812
166 Tejada S. Batle J.M. Ferrer M.D. Busquets-Cortés C. Monserrat-Mesquida M. Nabavi S.M. Therapeutic effects of hyperbaric oxygen in the process of wound healing Curr Pharm Des 25 2019 1682 1693 31269879
167 Ahmed R. Tariq M. Ali I. Asghar R. Khanam P.N. Augustine R. Novel electrospun chitosan/polyvinyl alcohol/zinc oxide nanofibrous mats with antibacterial and antioxidant properties for diabetic wound healing Int J Biol Macromol 120 2018 385 393 30110603
168 Bao F. Pei G. Wu Z. Zhuang H. Zhang Z. Huan Z. Bioactive self-pumping composite wound dressings with micropore array modified janus membrane for enhanced diabetic wound healing Adv Funct Mater 30 2020 2005422
169 Yu B. He C. Wang W. Ren Y. Yang J. Guo S. Asymmetric wettable composite wound dressing prepared by electrospinning with bioinspired micropatterning enhances diabetic wound healing ACS Appl Bio Mater 3 2020 5383 5394
170 Wu M. Zhang Y. Huang H. Li J. Liu H. Guo Z. Assisted 3D printing of microneedle patches for minimally invasive glucose control in diabetes Mater Sci Eng C 117 2020 111299
171 Chen S. Wang H. Su Y. John J.V. McCarthy A. Wong S.L. Mesenchymal stem cell-laden, personalized 3D scaffolds with controlled structure and fiber alignment promote diabetic wound healing Acta Biomater 108 2020 153 167 32268240
172 Ilhan E. Cesur S. Guler E. Topal F. Albayrak D. Guncu M.M. Development of Satureja cuneifolia-loaded sodium alginate/polyethylene glycol scaffolds produced by 3D-printing technology as a diabetic wound dressing material Int J Biol Macromol 161 2020 1040 1054 32544577
